Cargando…

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study

BACKGROUND/AIMS: Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could becom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koga, Akihiro, Matsui, Toshiyuki, Takatsu, Noritaka, Takada, Yasumichi, Kishi, Masahiro, Yano, Yutaka, Beppu, Takahiro, Ono, Yoichiro, Ninomiya, Kazeo, Hirai, Fumihito, Nagahama, Takashi, Hisabe, Takashi, Takaki, Yasuhiro, Yao, Kenshi, Imaeda, Hirotsugu, Andoh, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934595/ https://www.ncbi.nlm.nih.gov/pubmed/29743835 http://dx.doi.org/10.5217/ir.2018.16.2.223

Ejemplares similares

Validity of the usefulness of microvascular architecture and microsurface structure using magnifying endoscopy with narrow-band imaging in the colorectal neoplasm
por: Hisabe, Takashi, et al.
Publicado: (2013)

Efficacy of enteral nutrition in patients with Crohn’s disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis
por: Hirai, Fumihito, et al.
Publicado: (2019)

Crohn’s disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan
por: Yasukawa, Shigeyoshi, et al.
Publicado: (2018)

Risk factors for severity of colonic diverticular hemorrhage
por: Kinjo, Ken, et al.
Publicado: (2018)

Irregularly branched microvessels as visualized by magnifying endoscopy: a reliable marker for predicting deep submucosal invasion of superficial esophageal squamous cell carcinoma
por: Ono, Yoichiro, et al.
Publicado: (2020)

A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation
por: Kishi, Masahiro, et al.
Publicado: (2022)

Lipid is absorbed in the stomach by epithelial neoplasms (adenomas and early cancers): a novel functional endoscopy technique
por: Ohtsu, Kensei, et al.
Publicado: (2015)

Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy
por: Takatsu, Noritaka, et al.
Publicado: (2020)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Possible Earlier Diagnosis of Ulcerative Colitis-Associated Neoplasia: A Retrospective Analysis of Interval Cases during Surveillance
por: Hisabe, Takashi, et al.
Publicado: (2021)

Validity of conventional endoscopy using “non-extension sign” for optical diagnosis of colorectal deep submucosal invasive cancer
por: Hisabe, Takashi, et al.
Publicado: (2018)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
por: Kobayashi, Taku, et al.
Publicado: (2015)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
por: Huang, Vivian W., et al.
Publicado: (2015)

Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report
por: Garate, Ana Lorena Sousa de Vasconcelos, et al.
Publicado: (2021)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy
por: Parra, Rogério S., et al.
Publicado: (2018)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
por: Rolandsdotter, Helena, et al.
Publicado: (2017)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
por: Hisamatsu, Tadakazu, et al.
Publicado: (2018)

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease
por: Sekhri, Shaina, et al.
Publicado: (2021)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
por: Orts, Beatriz, et al.
Publicado: (2022)

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
por: Magro, Fernando, et al.
Publicado: (2017)

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
por: Park, Jihye, et al.
Publicado: (2023)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2017)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2019)

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
por: Theodoraki, Eirini, et al.
Publicado: (2021)

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study
por: Veisman, Ido, et al.
Publicado: (2021)

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
por: Gu, Bonita, et al.
Publicado: (2022)

Efficacy of endoscopy under general anesthesia for the detection of synchronous lesions in oral hypopharyngeal cancer
por: Ono, Yoichiro, et al.
Publicado: (2023)

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

The nature of the white opaque substance within colorectal neoplastic epithelium as visualized by magnifying endoscopy with narrow-band imaging
por: Imamura, Kentaro, et al.
Publicado: (2016)

Enterococcus durans TN-3 Induces Regulatory T Cells and Suppresses the Development of Dextran Sulfate Sodium (DSS)-Induced Experimental Colitis
por: Kanda, Toshihiro, et al.
Publicado: (2016)

Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions
por: Plasencia, Chamaida, et al.
Publicado: (2015)

The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study
por: Ishida, Natsuki, et al.
Publicado: (2020)

High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
por: Wilson, Aze, et al.
Publicado: (2021)

Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening
por: Ben-Shatach, Zohar, et al.
Publicado: (2022)

Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
por: Hirayama, Hisashi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_edv5vbc1ijce1nc085o5rng07c